Trial Profile
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Cedazuridine/decitabine (Primary) ; Decitabine; Decitabine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 31 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2024.
- 31 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2024.
- 15 Jun 2023 Interim Results (n=127) assessing safety of Decitabine/Cedazuridine (Astx727) in Lower-Risk Myelodysplastic Syndromes presented at the 28th Congress of the European Haematology Association